VIA
TVRD

Vantage Investment Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Vantage Investment Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$29K Hold
33
– – 0.01% 367
2018
Q2 		$23K Sell
33
-5
-13% -$2.54K 0.01% 399
2018
Q1 		$17K Hold
38
– – ﹤0.01% 458
2017
Q4 		$17K Sell
38
-9
-19% -$4.1K ﹤0.01% 480
2017
Q3 		$23K Buy
47
+14
+42% +$7.01K 0.01% 416
2017
Q2 		$18K Buy
33
+5
+18% +$3.17K 0.01% 448
2017
Q1 		$18K Buy
+28
New +$15K 0.01% 419

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vantage Investment Advisors's TVRD Position: Q3 2018 in Review

Vantage Investment Advisors held its Tvardi Therapeutics (TVRD) position steady in Q3 2018 at 33 shares worth $29K. The position accounts for 0.01% of the portfolio, ranked #367.

Vantage Investment Advisors first reported a position in TVRD in Q1 2017 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold TVRD as of Q3 2018.

  • Vantage Investment Advisors held 33 shares of Tvardi Therapeutics worth $29K as of Q3 2018.
  • Vantage Investment Advisors left its Tvardi Therapeutics share count unchanged in Q3 2018.
  • Tvardi Therapeutics made up 0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #367 holding.
  • Vantage Investment Advisors first reported a position in Tvardi Therapeutics in Q1 2017 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.